漆原 尚巳

Medicine & Life Sciences

1. Japan 100%
2. Databases 37%
3. Pharmaceutical Preparations 27%
4. Human Influenza 19%
5. Clinical Trials 18%
6. Safety 17%
7. Observational Studies 13%
8. Prescriptions 13%
9. Vaccination 13%
10. Xenopus 13%
11. Health 12%
12. Off-Label Use 12%
13. Raloxifene Hydrochloride 11%
14. Oocytes 11%
15. Health Insurance 11%
16. Cohort Studies 11%
17. Stevens-Johnson Syndrome 10%
18. Pediatrics 10%
19. Functional Food 10%
20. Postmenopausal Osteoporosis 10%
21. Hydroxymethylglutaryl-CoA Reductase Inhibitors 10%
22. Retrospective Studies 9%
23. Investigational Drugs 9%
24. Hypnotics and Sedatives 9%
25. Cholinergic Antagonists 9%
26. Osteoporosis 9%
27. N-Methylaspartate 9%
28. Marketing 8%
29. Food 8%
30. Randomized Controlled Trials 8%
31. Pharmacy 8%
32. Ethical Review 8%
33. baloxavir 8%
34. Confidence Intervals 7%
35. Life Style 7%
36. Datasets 7%
37. Adaptive Clinical Trials 7%
38. Drug Utilization 7%
39. Oseltamivir 7%
40. Cost-Benefit Analysis 7%
41. Dopamine Agonists 7%
42. Accidental Falls 6%
43. Publications 6%
44. Odds Ratio 6%
45. Informed Consent 6%
46. Emergencies 6%
47. Health Surveys 6%
48. European Union 6%
49. Type 2 Diabetes Mellitus 6%
50. Polypharmacy 6%